Eurofins to Offer GE's Cardiomyocytes in Toxicity Screening Services | GenomeWeb

NEW YORK (GenomeWeb News) — Eurofins said today that its Panlabs pharmacology services arm has signed an agreement with GE Healthcare giving it the exclusive right to offer GE's Cytiva cardiomyocytes for cardiotoxicity screening services.

Cardiomyocytes offer a cost-effective and time-efficient alternative to animal models for predictive cardiotoxicity testing in drug discovery and development, Eurofins said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.